The FDA has approved zoledronic acid for injection (Zometa; Novartis Pharmaceutical Corp, East Hanover, NJ), an inhibitor of osteoclastic bone resorption, for the treatment of hypercalcemia of malignancy (HCM).
The product was approved on the basis of two identical multicenter, randomized, double-blind, double-dummy trials of Zometa, 4 mg given as a 5-minute intravenous infusion, or pamidronate, 90 mg given as a 2-hour intravenous infusion, in 185 patients with HCM. Patients with recalcitrant or recurrent hypercalcemia received a second dose of Zometa.
Schwetz BA. Hypercalcemia of Malignancy. JAMA. 2001;286(13):1569. doi:10.1001/jama.286.13.1569